
Subject	Programme and Policy Committee Chair Report
---------	--

Category	For Information
----------	------------------------

Section A: Introduction

- This report provides the Board with an overview of the activities of the Programme and Policy Committee (PPC) since the Committee Chair last reported to the Board in December 2025.
- The PPC held an in-person meeting on 12-13 May 2026. During the meeting, the Committee discussed a number of important topics for the Alliance and agreed on recommendations which are being put forward to the Board at its 1- 2 July 2026 meeting for consideration.
- These decisions include the Gavi 6.0 Market Shaping Strategy, which is being presented on the Board's consent agenda, alongside other key Gavi 6.0 policies and approaches to be discussed by the Board on 1–2 July. These include: (i) the Vaccine Budget Policy, (ii) the Health Systems and Immunisation Strengthening Policy, (iii) the Strategic Approach to Campaign Optimisation, (iv) the Fragile and Humanitarian Approach, (v) the African Vaccine Manufacturing Accelerator, (vi) Alliance Roles and Responsibilities, (vii) Measurement and Evaluation Targets, and (viii) Fragility Support to Ukraine.
- Following the World Health Organization's (WHO) declaration on 17 May 2026 of a Public Health Emergency of International Concern (PHEIC) in respect of the outbreak of Ebola, the Gavi CEO proposed amending AVMA's key terms to allow African-manufactured vaccines approved under WHO Emergency Use Listing (EUL) to be designated a Priority Vaccine under AVMA. As this arose after the PPC met, this decision will appear in the decision block separately, as a recommendation from the CEO rather than the PPC, under the AVMA paper.
- The PPC Chair report is attached in the form of a presentation as Annex A and the list of PPC recommendations to the Board are attached as Annex B.

Annexes

Annex A: PPC Chair report

Annex B: PPC recommendations to Gavi Alliance Board

PROGRAMME AND POLICY COMMITTEE CHAIR REPORT

BOARD MEETING

Anne Schuchat

1-2 July 2026, Geneva, Switzerland

PPC Meeting, 12-13 May 2026

Discussion, Guidance and Information Items

- CEO Update including Gavi Leap and Gavi Strategy, Programmes and Partnerships Update
- Read out from the Audit & Finance Committee
- Joint Alliance Update on Country Delivery
- Market Shaping Retrospective

PPC Meeting, 12-13 May 2026

Recommendation Items:

- Gavi 6.0 Market Shaping Strategy
- Vaccine Budget Policy
- Health Systems and Immunisation Strengthening Policy
- African Vaccine Manufacturing Accelerator
- Strategic Approach on Campaign Optimisation
- Fragile and Humanitarian Approach
- Gavi 6.0 Measurement Framework targets
- Alliance Roles & Responsibilities
- Fragility Support to Ukraine



Thank you

REVIEW OF DECISIONS

PROGRAMME AND POLICY COMMITTEE
12-13 May, Geneva, Switzerland

Decision 1: Gavi 6.0 Market Shaping Strategy

Annex B

The Gavi Alliance Programme and Policy Committee recommended to the Gavi Alliance Board that it:

- Approve the Market Shaping Strategy 6.0 attached as Annex A to Doc 05b

Decision 2: Gavi 6.0 Programmatic Policies: Vaccine Budget Policy

The Gavi Alliance Programme and Policy Committee (PPC) **recommended** to the Gavi Alliance Board that it:

- **Approve** the Vaccine Budget Policy attached as Annex B to Doc 06a, as amended by the PPC.
- **Note:**
 - a) Additional resources in the financial forecast v23.2 (approximately US\$ 222 million) will be allocated following the revised prioritisation logic. This would likely cover most of the additional 2026 and 2027 needs from the draft v23.2 financial forecast.
 - b) If a funding gap in guaranteed budgets and the Initial Self Financing (ISF) floor persists, the Secretariat will conduct a holistic review of all Gavi funding envelopes to fill that gap and bring it to the Board for decision.
 - c) The Secretariat will conduct a review of the Vaccine Budget policy in 2028 and update it as needed.

Decision 3: Gavi 6.0 Programmatic Policies: Health Systems and Immunisation Strengthening Policy Annex B

The Gavi Alliance Programme and Policy Committee recommended to the Gavi Alliance Board that it:

- Approve the Health Systems and Immunisation Strengthening Policy attached as Annex B to Doc 06b.

Decision 4: African Vaccine Manufacturing Accelerator

The Gavi Alliance Programme and Policy Committee (PPC) **recommended** to the Gavi Alliance Board that it:

- a) **Approve** the programming of the additional US\$ 189 million in African Vaccine Manufacturing Accelerator (AVMA) pledges above the Board-approved US\$ 1 billion ceiling in support of a time-limited addendum to the AVMA key terms as set out in Annex A to Doc 07, known as "AVMA+".
- b) **Approve** the creation of two new funding windows within AVMA (i) a Vaccine Buy-Down Window and (ii) an Ecosystem Support Window.
- c) **Approve** the size of US\$ 50 million, targeted at the most critical risks to AVMA's delivery for the Ecosystem Support Window, with remaining funds allocated to the Vaccine Buy-down Window.
- d) **Request** the Secretariat provide to the PPC in October 2026 and to the Board in December 2026 proposals on an accelerated course-correction to AVMA's key terms limited at this stage to: (i) Accelerator payment levels (including the per-vial fill-finish cap) and (ii) scope of vaccines eligible for Milestone payments to take account of the changed operating context since AVMA's launch in 2024.

Decision 5: Gavi 6.0 Programmatic Approaches: Strategic Approach on Campaign Optimisation ^{Annex B}

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

- a) **Approve** the Campaign Optimisation Strategic Approach as outlined in Annex C to Doc 08a\$, as amended by the PPC.
- b) **Approve** the updated Co-financing Policy attached as Annex D to Doc 08a,

Decision 6: Gavi 6.0 Programmatic Approaches: Fragile and Humanitarian Approach ^{Annex B}

The Gavi Alliance Programme and Policy Committee recommended to the Gavi Alliance Board that it:

- Approve the proposed reprioritisation of use cases under the Fragile and Humanitarian Approach attached as Annex A to Doc 8b.

Decision 7: Gavi 6.0 Measurement Framework targets & Update from the EAC

The Gavi Alliance Programme and Policy Committee (PPC) **recommended** to the Gavi Alliance Board, that it:

- a) **Approve** the Gavi 6.0 mission and strategy measurement framework targets, as amended by the PPC and subject to alignment on targets for the indicators on zero-dose (M4) and completed series of IPV (SG1b.2) with the Alliance Technical Working Group;
- b) **Note** the update on the evidence prioritisation approach and Evaluation Policy revision process.

Decision 8: Alliance Roles & Responsibilities

The Gavi Alliance Programme and Policy Committee recommended to the Gavi Alliance Board that it:

- Approve the allocation of an additional US\$ 30 million to the Foundational Fund, increasing total Global/Regional Foundations resourcing to US\$ 190 million, to address high-priority risks.

Decision 9: Fragility support to Ukraine

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

- a) **Approve, exceptionally**: (1) a no cost extension of Ukraine's US\$ 10 million fragility support as approved by the Gavi Board in December 2025, from 1 July 2026 until 30 June 2027; and (2) a costed extension of US\$ 6 million until 31 December 2027 contingent on additional funds being available through a special programme to support Ukraine.
- b) **Request** that the Secretariat explores alternative funding mechanisms to finance the Gavi Board approved US\$ 10 million fragility support to release pressure from the funds in the Gavi Resilience Mechanism.

Thank you